NuVision Biotherapies confirms global expansion

The UK-based tissue-therapy company will introduce its products and services to ophthalmologists in the Netherlands

Man with arm outstretched with a contact lens on a finger

NuVision Biotherapies is continuing to expand its global presence through the support of a partnership with Laméris.

The expansion will see the UK-based company, which manufactures and deploys bespoke treatments developed from amniotic membrane, release its products to ophthalmologists in the Netherlands, where they will be used in an outpatient setting to support ocular care.

Based on 15 years of research at the University of Nottingham, NuVision’s products use dried amniotic membrane which is held in place on the surface of the eye by a specially designed contact lens. The lens is placed on the surface of the eye without the need for surgery. 

Over the last five years the combination of NuVision’s amniotic membrane, Omnigen, and contact lens, OmniLenz, has been used in over 130 UK hospitals for the treatment of inflammation and damage to the surface of the eye following traumatic injury, eye surgery, and in chronic diseases.  

The partnership with Laméris, a primary organiser of outpatient clinics in the Netherlands, sees NuVision further expand its global footprint as it now operates in seven countries.

Commenting on the announcement, CEO at NuVision, Andy Hill, explained: “Omnigen and OmniLenz are currently in use at 130 hospitals across the UK, which is a crucial market for us. However, global expansion is an essential part of our growth strategy over the next few years. Our partnership with Laméris and introduction into the Netherlands is a pivotal moment, demonstrating the requirement for, and viability of, innovative new technologies and therapies in European ocular care. We are looking forward to working closely with Laméris to widen accessibility to amnion within the Netherland’s ophthalmic and optometric markets.”

Business development manager for surgical at Laméris, Marco Erenstein, said: “We are thrilled with the partnership with NuVision Biotherapies, whose vision resonates with our mission to innovate and elevate eye care solutions. Introducing NuVision in the Netherlands fills us with pride, as it represents our commitment to advancing the field and providing cutting-edge options for both patients and medical professionals to excel in their practice.”